CAESARSTONE LTD (CSTE) Fundamental Analysis & Valuation

NASDAQ:CSTE • IL0011259137

Current stock price

1.33 USD
-0.01 (-0.75%)
Last:

This CSTE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CSTE Profitability Analysis

1.1 Basic Checks

  • CSTE had negative earnings in the past year.
  • CSTE had a negative operating cash flow in the past year.
  • In the past 5 years CSTE reported 4 times negative net income.
  • In multiple years CSTE reported negative operating cash flow during the last 5 years.
CSTE Yearly Net Income VS EBIT VS OCF VS FCFCSTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • CSTE's Return On Assets of -34.53% is on the low side compared to the rest of the industry. CSTE is outperformed by 90.24% of its industry peers.
  • CSTE has a worse Return On Equity (-95.01%) than 90.24% of its industry peers.
Industry RankSector Rank
ROA -34.53%
ROE -95.01%
ROIC N/A
ROA(3y)-20.1%
ROA(5y)-13.14%
ROE(3y)-47.61%
ROE(5y)-30.48%
ROIC(3y)N/A
ROIC(5y)N/A
CSTE Yearly ROA, ROE, ROICCSTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • Looking at the Gross Margin, with a value of 18.45%, CSTE is doing worse than 78.05% of the companies in the same industry.
  • CSTE's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CSTE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.91%
GM growth 5Y-7.69%
CSTE Yearly Profit, Operating, Gross MarginsCSTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CSTE Health Analysis

2.1 Basic Checks

  • CSTE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CSTE has about the same amount of shares outstanding.
  • The number of shares outstanding for CSTE has been increased compared to 5 years ago.
  • The debt/assets ratio for CSTE has been reduced compared to a year ago.
CSTE Yearly Shares OutstandingCSTE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
CSTE Yearly Total Debt VS Total AssetsCSTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.12, we must say that CSTE is in the distress zone and has some risk of bankruptcy.
  • CSTE has a worse Altman-Z score (1.12) than 90.24% of its industry peers.
  • CSTE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • CSTE's Debt to Equity ratio of 0.00 is amongst the best of the industry. CSTE outperforms 92.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.12
ROIC/WACCN/A
WACC8.26%
CSTE Yearly LT Debt VS Equity VS FCFCSTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • CSTE has a Current Ratio of 1.83. This is a normal value and indicates that CSTE is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.83, CSTE perfoms like the industry average, outperforming 41.46% of the companies in the same industry.
  • CSTE has a Quick Ratio of 1.15. This is a normal value and indicates that CSTE is financially healthy and should not expect problems in meeting its short term obligations.
  • CSTE has a Quick ratio of 1.15. This is comparable to the rest of the industry: CSTE outperforms 46.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.15
CSTE Yearly Current Assets VS Current LiabilitesCSTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CSTE Growth Analysis

3.1 Past

  • CSTE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.42%.
  • CSTE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.38%.
  • The Revenue has been decreasing by -3.97% on average over the past years.
EPS 1Y (TTM)-74.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.14%
Revenue 1Y (TTM)-10.38%
Revenue growth 3Y-16.84%
Revenue growth 5Y-3.97%
Sales Q2Q%-3.5%

3.2 Future

  • Based on estimates for the next years, CSTE will show a very strong growth in Earnings Per Share. The EPS will grow by 22.07% on average per year.
  • Based on estimates for the next years, CSTE will show a small growth in Revenue. The Revenue will grow by 2.21% on average per year.
EPS Next Y32%
EPS Next 2Y22.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1.59%
Revenue Next 2Y2.21%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CSTE Yearly Revenue VS EstimatesCSTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
CSTE Yearly EPS VS EstimatesCSTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. CSTE Valuation Analysis

4.1 Price/Earnings Ratio

  • CSTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CSTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSTE Price Earnings VS Forward Price EarningsCSTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSTE Per share dataCSTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • CSTE's earnings are expected to grow with 22.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CSTE Dividend Analysis

5.1 Amount

  • CSTE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CSTE Fundamentals: All Metrics, Ratios and Statistics

CAESARSTONE LTD

NASDAQ:CSTE (4/30/2026, 8:00:02 PM)

1.33

-0.01 (-0.75%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)03-04
Earnings (Next)05-13
Inst Owners12.53%
Inst Owner Change-1.33%
Ins Owners3.76%
Ins Owner Change0%
Market Cap45.99M
Revenue(TTM)397.23M
Net Income(TTM)-137.57M
Analysts82.86
Price Target4.08 (206.77%)
Short Float %2.66%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.53%
Min EPS beat(2)-35.23%
Max EPS beat(2)-23.84%
EPS beat(4)1
Avg EPS beat(4)-31.91%
Min EPS beat(4)-79.74%
Max EPS beat(4)11.15%
EPS beat(8)3
Avg EPS beat(8)-23.7%
EPS beat(12)3
Avg EPS beat(12)-218.49%
EPS beat(16)4
Avg EPS beat(16)-180.02%
Revenue beat(2)1
Avg Revenue beat(2)0.69%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)2.57%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-7.26%
Max Revenue beat(4)2.57%
Revenue beat(8)2
Avg Revenue beat(8)-4.4%
Revenue beat(12)3
Avg Revenue beat(12)-5.46%
Revenue beat(16)3
Avg Revenue beat(16)-4.83%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS11.49
BVpS4.19
TBVpS4.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -34.53%
ROE -95.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.45%
FCFM N/A
ROA(3y)-20.1%
ROA(5y)-13.14%
ROE(3y)-47.61%
ROE(5y)-30.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.91%
GM growth 5Y-7.69%
F-Score3
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.64%
Cap/Sales 2.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.83
Quick Ratio 1.15
Altman-Z 1.12
F-Score3
WACC8.26%
ROIC/WACCN/A
Cap/Depr(3y)53.89%
Cap/Depr(5y)59.94%
Cap/Sales(3y)2.2%
Cap/Sales(5y)2.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.14%
EPS Next Y32%
EPS Next 2Y22.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.38%
Revenue growth 3Y-16.84%
Revenue growth 5Y-3.97%
Sales Q2Q%-3.5%
Revenue Next Year1.59%
Revenue Next 2Y2.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-319.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-219.31%
OCF growth 3YN/A
OCF growth 5YN/A

CAESARSTONE LTD / CSTE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CAESARSTONE LTD (CSTE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CSTE.


Can you provide the valuation status for CAESARSTONE LTD?

ChartMill assigns a valuation rating of 1 / 10 to CAESARSTONE LTD (CSTE). This can be considered as Overvalued.


How profitable is CAESARSTONE LTD (CSTE) stock?

CAESARSTONE LTD (CSTE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for CSTE stock?

The Earnings per Share (EPS) of CAESARSTONE LTD (CSTE) is expected to grow by 32% in the next year.